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 NON-ENZYMATIC GLYCATION OF SYNTHETIC MICROTISSUES FOR 
THREE-DIMENSIONAL DIABETIC WOUND HEALING 
 
EMILY SOMMER TKAC 
ABSTRACT 	  	  
Background: Diabetes is a worldwide epidemic, and the number of those affected is only 
growing. Diabetes is characterized by hyperglycemia due to the body’s inability to 
produce or properly use insulin. Hyperglycemia contributes to diabetic complications in 
several ways, one of which is promoting glycation. Glycation is the non-enzymatic 
glucosylation of proteins, and because glycation is adventitious, the process most 
commonly occurs on proteins with long half-lives, such as collagen. Glycation greatly 
changes collagen’s mechanical and biochemical properties. Glycation leads to the 
production of advanced glycation end products (AGEs) that have been shown to 
contribute to the complications seen in diabetes in one of two ways: establishment of 
crosslinks between molecules in the basement membrane of the extracellular matrix, 
altering cellular function, or interactions between AGEs and AGE receptors on the cell 
surface. Diabetes greatly impairs the body’s ability to heal wounds, and it is thought that 
the AGEs produced by glycation greatly contribute this phenomenon. However, it is not 
fully understood, what direct role AGEs and glycated collagen plays in the wound 
healing process. Three-dimensional microtissue models have been developed for the 
purpose of studying wound healing, and the creation of a three-dimensional microtissue 
	  	   vii 
with glycated collagen allows for investigation into the specific role that glycated 
collagen plays on both the mechanical and biochemical properties of the wound closure 
and the healing process. 
Methods: In order to study the effect of glycated collagen on wound healing, a protocol 
to make glycated collagen must first be developed. To make glycated collagen, soluble 
rat-tail type I collagen will be incubated with 250mM ribose at 4°C for a minimum of 
five days to allow the collagen to become glycated. The glycated collagen will be used to 
make a collagen gel, and then papain buffer will digest the gel. The extent of glycation 
will be determined through quantifying the digested glycated collagen gel’s 
autofluorescence, absorbance, and changes that can be perceived visually. Once it is 
confirmed that the collagen has been glycated, it will be incorporated into a microtissue 
model based on a previously published protocol. The microtissue will then be wounded 
with a micromanipulator and 16-gauge needle, and visualized via time-lapse microscopy. 
The rate at which the wound closes will be compared in microtissues made with glycated 
collagen to those made with non-glycated collagen.  
Results: Glycation of collagen was unable to be confirmed consistently by measuring the 
autofluorescence of the collagen gel digests. However, the absorbance of the collagen gel 
digest was used to determine that the collagen was 43.16% glycated and visual changes 
in the collagen gels made with glycated collagen was also observed. Microtissues were 
able to successfully form with the glycated collagen, and were able to be used to compare 
wound healing in normal microtissues against those made with glycated collagen.  
  
	  	   viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………?..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS ................................................................................................... v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES ............................................................................................................ xi 
LIST OF ABBREVIATIONS ........................................................................................... xii 
INTRODUCTION ............................................................................................................... 1 
SPECIFIC AIMS ............................................................................................................... 17 
METHODS ........................................................................................................................ 18 
RESULTS .......................................................................................................................... 25 
DISCUSSION ................................................................................................................... 37 
LIST OF JOURNAL ABBREVIATIONS ........................................................................ 40 
REFERENCES .................................................................................................................. 41 
	  	   ix 
CURRICULUM VITAE ................................................................................................... 47 	  
 
  
	  	   x 
LIST OF TABLES 
 
 
Table Title Page 
1 Autofluorescence of collagen gels made with control, 0 
mM collagen, 250 mM ribose incubated with collagen left 
open to oxidize, and 250 mM ribose with collagen 
25 
2 The absorbance of collagen gel digests measured at 340 
nm 
29 
 
 
  
	  	   xi 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Effects of Insulin on the Cell  4 
2 Mechanisms of pancreatic β-cells death 5 
3 Pathophysiology of Type 2 Diabetes Mellitus 6 
4 Normal Stages of Wound Healing 9 
5 Advanced Glycation End Product Formation 12 
6 The extracellular and intracellular effects of AGEs 13 
7 Microtissue Development 15 
8 Device Fabrication and Master Stamps 19 
9 Autofluorescence of collagen gel digests with different 
spectrofluorometer emission settings 
26 
10 Eighteen collagen gel digests before autofluorescence 
measurement on spectrofluorometer 
27 
11 Autofluorescence (au) of eighteen collagen gel digests 28 
12 Visual changes observed in collagen gel digests made 
from glycated and non-glycated collagen 
30 
13 Wound Healing in Two Microtissues Part 1 32 
14 Wound Healing in Two Microtissues Part 2 34 
15 Glycated Microtissue Wound Healing 36 
 
 xii 
LIST OF ABBREVIATIONS 
AGEs............................................................................. Advanced Glycation End Products 
AU................................................................................................................ Arbitrary Units 
DMEM....................................................................... Dulbecco’s Modified Eagle Medium  
EDTA................................................................................ Ethylenediaminetetraacetic acid 
HEPES............................................... 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
PBS............................................................................................ Phosphate Buffered Saline 
PDMS................................................................................................ Polydimethylsiloxane 
TD1............................................................................................................. Type I Diabetes 
TD2............................................................................................................ Type II Diabetes 
 
	  1 
INTRODUCTION 
 
  
Since 1980, the worldwide prevalence of diabetes mellitus has quadrupled 
(“WHO | 10 facts on diabetes,” n.d.), and is estimated to affect 9.4% of the United States’ 
population. Diabetes is a complex, multifaceted disease in which genetics, socioeconomic 
background, culture, and lifestyle are all factors that influence the prevalence of the 
disease. Because of this, diabetes has the potential to affect virtually anyone regardless of 
age, ethnicity, or sex. However, certain factors have been identified which increase the 
risk of developing diabetes. Some factors include, but are not limited to, having a pre-
existing condition such as polycystic ovarian syndrome, depression, cardiovascular 
disease, high blood pressure, high levels of triglycerides, being over the age of forty-five, 
obesity, reduced physical activity, smoking, or having a family member with diabetes	  
(Chow, Foster, Gonzalez, & McIver, 2012).  
Diabetes not only greatly affects the life of those living with the disease; it also 
has a tremendous economic impact on the healthcare system. In 2018, the estimated 
annual cost of diagnosed diabetes in the United States rose to $327 billion dollars, from 
$245 billion dollars in 2012 (“National Diabetes Statistics Report | Data & Statistics | 
Diabetes | CDC,” 2018) and the average medical expenditures cost individuals with 
diabetes an average of $16,752 a year (Riddle & Herman, 2018). The swelling cost of 
living with diabetes is particularly alarming since individuals living in poverty or low-
income households have an increased risk of developing diabetes (Hsu et al., 2012). Due 
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to the high costs of treating diabetes, as well as the growing prevalence of the disease, it 
is imperative that research on the disease with the goal of improving effectiveness and 
reducing the cost of treatment, management and prevention be continued. 
American Indians, Alaskan natives, African Americans, Hispanics, Latinos, Asian 
Americans, Native Hawaiians, and Pacific Islanders all have an increased risk of 
developing diabetes. The reason for this ethnic disparity is due to several elements, 
including biological factors, social factors, and even the heath care system itself. Several 
of these ethnicities, when compared to other ethnic groups, tend to have increased insulin 
resistance or augmented insulin secretion, higher obesity prevalence, and worse glycemic 
control (“Risk Factors for Type 2 Diabetes | NIDDK,” n.d.). Minorities may live in areas 
in which access to healthy, nutritious food and exercise is limited, and psychological 
stressors related to crime and financial burdens are linked to poor health. Management of 
chronic diseases and prevention is more difficult in lower socioeconomic areas, as 
individuals may not have medical insurance or access to health care resulting in higher 
risk of developing diabetes, mismanagement of the disease (Spanakis & Golden, 2013).  
Additionally, diabetes affects nearly 25% of those who have served in the armed forces, 
which is much greater than 9.4% of the general population that is affected by diabetes. 
The reasons for this disparity is similar to the one seen in ethnic minority groups; when 
compared to the overall population, veterans tend to have a high obesity rate, and low 
incomes which have adverse affects on health (“Veterans and Diabetes,” n.d.).  
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Diabetes: The Disease  
Diabetes mellitus is a chronic, metabolic condition that causes deregulation of 
blood glucose levels by a deficiency in insulin secretion, insulin action, or both 
(“Diagnosis and Classification of Diabetes Mellitus,” 2014). Insulin is an extremely 
important hormone in metabolism, as it regulates the uptake of glucose from blood into 
cells (“WHO | Diabetes mellitus,” n.d.).  Blood glucose homeostasis depends on a 
sensitive feedback loop involving pancreatic β-cell and insulin sensitive tissues. In 
healthy patients, glucose in the blood primarily stimulates pancreatic β-cells to secrete 
insulin, although other macronutrients, hormones, and neural impact can also influence 
insulin secretion. Once insulin is released from secretory granules, it can act on insulin-
sensitive tissue, primarily skeletal muscle tissue, adipose tissue, and the liver (Kahn, 
Cooper, & Del Prato, 2014). Insulin then binds to receptors on target tissues and initiates 
a number of pathways within the cell that eventually results in restoring blood glucose 
homeostasis (Figure 1). If this delicate pathway is disrupted however, serious health 
concerns and diseases, such as diabetes, can arise.  
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Figure 1. Effects of Insulin on the Cell. This diagram shows the several signaling 
pathways activated by insulin binding as well as the effects on insulin on the cell 
(Wilcox, 2005).  
 
 Type 1 diabetes, also called insulin-dependent or juvenile-onset diabetes, is an 
auto-immune disease in which the insulin-producing β-cells of the pancreas are inflamed 
or destroyed (Figure 2). Because of this, insulin cannot be sufficiently produced and 
glucose cannot be taken from the blood into cells, resulting in hyperglycemia. The loss of 
pancreatic β-cells can be due to several mechanisms. CD8+ T cells are the most 
numerous cell type found in the inflamed region of the pancreas, but CD4+ T cells, B-
lymphocytes, plasma cells, and macrophages also contribute to pathogenesis of 
pancreatic β-cells (Atkinson, Eisenbarth, & Michels, 2014). Individuals with type I 
diabetes require insulin injections in order to manage their blood glucose levels (“Type 1 
Diabetes | Basics | Diabetes | CDC,” 2018).  
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Figure 2. Mechanisms of pancreatic β-cells death. While pancreatic β-cell death can be 
seen in both type 1 (T1D) and type 2 diabetes (T2D) this schematic highlights the 
differences in the methods of destruction (Cnop et al., 2005).  
 
 
Type 2 diabetes, which is also called adult-onset diabetes, accounts for about 90% 
of diagnosed cases of diabetes. It is characterized by the body’s inability to appropriately 
respond to the insulin produced by pancreatic β-cells, or the β-cells themselves do not 
produce an adequate amount of insulin needed to accurately regulate blood glucose 
levels. Insulin resistance occurs when the pancreas sufficiently secretes enough insulin, 
but the tissues do no respond properly to the insulin. As a result, the pancreas tends to 
produce even more insulin, in an effort to overcome this response. Despite this, 
hyperglycemia can still occur (“Insulin Resistance & Prediabetes | NIDDK,” n.d.). The 
dysfunction seen in pancreatic β-cells in type 2 diabetes can be due to deviations in β-
cells function or loss of pancreatic β-cells mass (Figure 2) (Cnop et al., 2005). Both types 
of diabetes result in hyperglycemia (Figure 3), and chronic hyperglycemia leads to long-
term damage and dysfunction affecting several different systems of the body; the disease 
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can trigger retinopathy, neuropathy, nephropathy, and cardiovascular disease (“WHO | 
About diabetes,” n.d.).  
 
 
 
Figure 3. Pathophysiology of Type 2 Diabetes Mellitus. This diagram demonstrates 
that impaired insulin secretion, insulin resistance, chronic inflammation, and other factors 
contribute to hyperglycemia seen in type 2 diabetes. This diagram also shows potential 
therapeutic agents that can be used to try to regulate blood glucose levels (DeFronzo et 
al., 2015).  
 
 
Complications associated with Diabetes  
Diabetes is a body-wide condition, and if not properly controlled, has the potential 
to affect and damage several body systems. The disease can have both macrovascular and 
microvascular complications, meaning it can damage the large vessels of the heart, brain 
and legs as well as cause damage to the eyes, kidneys, nerves, and feet. The digestive 
system, lungs, teeth, gums, reproductive organs, and skin can all be harmed by diabetes 
(Services, n.d.). Because of this, diabetes is a difficult disease to regulate and manage, 
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due to having to treat and prevent complications in addition to just controlling the 
diabetes itself.  
 Diabetes has a significant impact on the body’s ability to heal a wound. While it 
is possible for wounds to heal in diabetic individuals, the wounds often heal slower due to 
the wound healing process being greatly impaired by the disease (Sharp & Clark, 2011).  
A non-healing wound is likely to suffer from infection or additional trauma, which only 
further exacerbates the wound healing process. It is estimated that of those living with 
diabetes, 15% will develop chronic wound and have a 15-fold increased risk of 
amputation (“Wound Healing and People with Diabetes - Inova,” n.d.).  Additionally, the 
estimated annual cost of chronic wounds is $31.7 billion dollars, with diabetic foot ulcers 
being one of the highest total costs (Nussbaum et al., 2018).  
Non-healing wounds, especially on the feet, are particularly worrisome for 
diabetic patients. Foot ulcers will affect 25% of all diabetic patients, and 85% of all 
diabetes-related amputations are preceded by foot ulcerations (“Diabetic Wound Care | 
Foot Health | Patients | APMA,” n.d.). Risk factors for developing a foot ulcer include 
peripheral neuropathy, which accounts for nearly 90% of foot ulcers, as well as 
peripheral vascular disease. Neuropathy results in reduced feeling or sensation in tissues, 
which potentially allows for tissue damage and pain to go unnoticed.  This involves the 
destruction of both motor and sympathetic nerve destruction. Loss of motor function 
results in loss of normal foot arch and an increase in pressure points, which can lead to 
pressure necrosis. Damage to sympathetic nerves result in reduced sweating and 
moisture, which causes dry skin and fissures in the skin, and increases the risk of 
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infection (Greenhalgh, 2003). Peripheral vascular disease can cause reduced nutrient and 
oxygen delivery to tissues, hindering the wound healing process (Sharp & Clark, 2011).  
 
 
Effects of Diabetes on Wound Healing  
The cellular events seen in wound healing can be divided into four overlapping 
stages: hemostasis, inflammation, proliferation and then remodeling (Figure 4). However, 
diabetes has the potential to hinder each stage, compromising the wound healing process. 
Immediately following a lesion, hemostasis begins. Hemostasis involves 
vasoconstriction, release of pro-inflammatory mediators, platelet activation and 
aggregation of thrombocytes and platelets in a fibrin network. This fibrin network helps 
to reduce blood loss, prevent invasion of microorganisms, and provides a temporary 
matrix that is used to assist in cell migration (Gonzalez, Costa, Andrade, & Medrado, 
2016). Diabetes is associated with poor vascular supply, and this reduced oxygen source 
accounts for some of the complications seen in diabetic wound healing. Hypoxia weakens 
the efficiency of immune cells such as neutrophils and macrophages (Sharp & Clark, 
2011). The cells of diabetic patients also tend to have a thickened perivascular basement 
membrane, which can obstruct the delivery of micronutrients. The thickened membrane 
can act as a trap for immune cells making leukocyte migration more difficult and 
contribute to the increased risk of infection when compared to normal tissue (Greenhalgh, 
2003).  
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Figure 4. Normal Stages of Wound Healing. This model shows the typical steps of 
wound healing in a healthy tissue: hemostasis, inflammation, proliferation, and 
remodeling (Sun, Siprashvili, & Khavari, 2014).  
 
 
The inflammatory stage of wound healing is characterized by an invasion of 
leukocytes to the lesion. Neutrophils are the first cells to arrive to the injury and release 
cytokines, which in turn amplify the inflammatory response. Neutrophils also have an 
antimicrobial function; they are involved in phagocytosis, degranulation and generation 
of neutrophil extracellular traps (Wang, Huang, Horng, Yeh, & Chen, 2018). Due to the 
damage of blood vessels seen in diabetes, the neutrophil response is slower, and so there 
are a reduced number of neutrophils. Inflammatory cytokines are present in the wound 
site longer than healthy tissue, to compensate for the diminished number of leukocytes, 
and prolongs the inflammation response. The antimicrobial and phagocytic function of 
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the neutrophils, over time, can cause edema and destruction of new extracellular matrix, 
compromising healing (Sharp & Clark, 2011).  
The proliferation stage of wound healing is responsible for the closure of the 
lesion – which includes angiogenesis, fibroplasia and re-epithelialization. Cell movement 
is critical for this stage, and as explained previously, is hindered in diabetes. 
Additionally, the high number of pro-inflammatory components present at the wound site 
tends to dominate the proliferation components, slowing the proliferation stage. 
Fibroblast activity is also reduced, slowing the deposition of collagen and complicating 
healing (Sharp & Clark, 2011).   
The goal of the remodeling stage of wound healing is to attain maximum tensile 
strength of the tissue through restructuring of the extracellular matrix. The granulation 
tissue of the wound is remodeled and forms scar tissue, which has increased collagen 
content but decreased cellular and vascular components (Gonzalez, Costa, Andrade, & 
Medrado, 2016). The tensile strength of the collagen seen in diabetic patients is reduced, 
and has an increased tendency to break when compared to normal collagen. Since the 
scar tissue is weaker, diabetics also have an increased risk of ulcer recurrence (Sharp & 
Clark, 2011). 
 
 
 
Hyperglycemia and Advanced Glycation End Products  
  
 Inadequate glucose control contributes to impaired healing of diabetic wounds. 
Microorganisms thrive on increased glucose available in the bloodstream, encouraging 
infection (Greenhalgh, 2003). High glucose concentrations also weaken the ability of 
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leukocytes to function properly, leading to proliferation of bacteria and infection (Sharp 
& Clark, 2011). Additionally, hyperglycemia promotes glycation. Glycation is the non-
enyzmatic glucosylation of proteins, and because glycation is adventitious, the process 
most commonly occurs on proteins with long half-lives, such as collagen. Collagen, a 
component of the extracellular matrix and the most abundant protein in the body, is the 
basis for the functional properties of several tissues, such as renal basement membrane 
and the cardiovascular system (Paul & Bailey, 1996).  Glycation greatly changes 
collagen’s mechanical and biochemical properties in a number of ways. Specifically, it 
alters collagen’s ability to form aggregates and modifies the electrical charge of collagen, 
affecting the protein’s interactions (Paul & Bailey, 1996). It also results in collagen 
having decreased solubility, increased stiffness and stability, and decreased sensitivity to 
enzymes (Sajithlal, Chithra, & Chandrakasan, 1998). Since glycation is dependent on 
reducing sugar concentration, it is enhanced in diabetic patients (Anguizola et al., 2013). 
Additionally because collagen is such a central and significant protein in the body, its 
modification is directly involved in the pathogenesis of diabetes (Sajithlal, Chithra, & 
Chandrakasan, 1998).  
Hyperglycemia also contributes to formation of advanced glycation end products 
(AGEs). AGEs are formed when aldehyde groups on glucose or other reactive sugars 
react with free amino groups of amino acids (most commonly lysine residues) to form 
Schiff bases. This process happens non-enzymatically, is unstable, and happens over the 
course of a few hours (Van Putte, De Schrijver, & Moortgat, 2016). Further 
rearrangement of the Schiff base leads to the more stable Amadori product, a ketoamine. 
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The reactions that form Schiff bases and Amadori products are reversible, but can 
undergo additional irreversible reactions with amino acids residues to form protein 
adducts or protein crosslinks. Alternatively, Schiff bases and Amadori products can 
undergo oxidation or dehydration reactions to form AGEs (Figure 5).  
 
Figure 5. Advanced Glycation End Product Formation. This figure shows the reaction 
between glucose and a protein, producing the reversible Schiff base, and then the more  
stable Amadori Base, and the eventual formation of an AGE (Gkogkolou & Böhm, 
2012).  
 
 
AGEs have been shown to contribute to the complications seen in diabetes in one 
of two ways: establishment of crosslinks between of molecules in the basement 
membrane of the extracellular matrix, altering cellular function, or interactions between 
AGEs and AGE receptors on the cell surface (Goldin, Beckman, Schmidt, & Creager, 
2006). The crosslinks produced by AGEs in the extracellular matrix increase stiffness of 
the membrane, and also activate transforming growth factor beta-receptors, which 
stimulates growth and increases the production of the extracellular matrix components. 
AGEs that bind to AGE receptors on the cell surface affect numerous intracellular 
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pathways via signaling cascades (Figure 6). AGEs lead to increased reactive oxygen 
species production, inflammation, and apoptosis. AGEs also reduce the activity of nitric 
oxide, which may be contributing to impaired vasodilation seen in diabetic patients 
(Goldin Alison, Beckman Joshua A., Schmidt Ann Marie, & Creager Mark A., 2006). In 
addition to diabetes, AGEs have been shown to have detrimental effects in other diseases 
such as rheumatoid arthritis, Alzheimer’s disease, and end-stage renal disease (Singh, 
Barden, Mori, & Beilin, 2001).  
 
 
 
Figure 6. The extracellular and intracellular effects of AGEs. AGEs alter the normal 
activity of cells via several mechanisms, and these changes contribute to many of the 
complications seen in diabetes (Goldin, Beckman, Schmidt, & Creager, 2006). 
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Microtissues  
The mechanical properties of the extracellular matrix play an extremely important 
role in maintaining normal cellular function. And while the glycation-driven 
modifications on collagen have been identified, the direct role of glycated collagen and 
AGEs on wound healing is not yet fully understood. However, three-dimensional 
microtissues could be used to mimic diabetic-like changes, as well as to examine the role 
of glycated collagen on gap closure during wound healing. These microtissues, composed 
of fibroblast cells embedded in a type I collagen matrix, have been developed to examine 
the cellular and biophysical properties of three-dimensional wound healing in vitro 
(Sakar et al., 2016). The microtissues are formed in the wells of a polydimethylsiloxane 
(PDMS) device, and are suspended by cantilevers that constrain the microtissue. The 
microtissues can then be damaged with a hypodermic needle or microsurgical knife to 
mimic a wound, and time-lapse confocal microscopy can be used to observe the healing 
process (Figure 7). 
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A. B.	         
         C.    
Figure 7. Microtissue Development. A. This schematic shows the process of developing 
and wounding 3D microtissues. The cells and collagen matrix suspension are added 
directly into the PDMS device. The microtissues form after collagen has been allowed to 
polymerize. Formed microtissues can then be wounded directly in the PDMS device 
(Sakar et al., 2016).  B and C. Pictures of microtissues in wells of the PDMS device.  
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Two-dimensional wound healing models discovered that gap closure is 
accomplished through cells migrating across the wound surface in an adhesion dependent 
manner, or through a multicellular actin purse string mechanism (Sakar et al., 2016). 
While these discoveries may explain the mechanisms involved in re-epithelialization, 
they fail to consider the reconstruction of the three-dimensional architecture of the tissue. 
Wounding of three-dimensional microtissues have shown that fibroblasts close the wound 
through force-dependent contraction of the whole tissue, circumferential cell movement 
to the wound edge, and assembly of fibronectin scaffolding that facilitates gap closure, 
which differs from what is observed in two-dimensional wound healing (Sakar et al., 
2016). Since the three-dimensional model more closely mimics in vivo stromal tissue gap 
closure during wound healing, the creation of a three-dimensional microtissue with 
glycated collagen allows for investigation into the specific role that glycated collagen 
plays on both the mechanical and biochemical properties of the wound closure and the 
healing process. 
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Specific Aims 
 
It is known that diabetic patients have increased amounts of glycated collagen, 
and glycation changes both the mechanical and biochemical properties of proteins. It is 
not fully understood, however, what direct role glycated collagen plays in the wound 
healing process. Firstly, protocol to make microtissues from glycated collagen must be 
developed. To make glycated collagen, soluble rat-tail type I collagen will be incubated 
with 250mM ribose at 4°C for a minimum of five days to allow the collagen to become 
glycated. The extent of glycation will be determined through collagen autofluorescence, 
absorbance, and changes that can be seen visually. Once it is confirmed that the collagen 
has been glycated, it will be incorporated into a microtissue model using NIH/3T3 
fibroblast cells based on a previously published protocol (Sakar et al., 2016). The 
microtissue will then be wounded with a micromanipulator and 16-gauge needle, and 
visualized via time-lapse microscopy. The rate at which the wound closes will be 
compared in microtissues made with glycated collagen to those made with non-glycated 
collagen.   
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METHODS 
 
Device Fabrication  
To make master devices, three inch wafers were dehydrated at 200°C for thirty 
minutes, and then plasma cleaned for five minutes. SU-8 2002 photoresist was dispensed 
to the wafer base and spun to evenly coat the wafer and to promote adhesion. It was then 
baked at 95°C for two minutes, exposed to 100mJ of energy via ultraviolet light, and 
baked again at 95°C for two minutes. SU-8 2050 photoresist was then added to the cap 
layer and spun to fully spread out the photoresist. The wafer was then baked again at 
95°C for 2.75 hours and let cool overnight. A mixture of S1813 photoresist and SU-8 
2010 was made and agitated overnight. The mixture was poured onto the wafer, and spun 
again. It was baked at 95°C for thirty minutes and then cooled overnight. The wafer was 
then exposed to 450mJ of energy, baked at 65°C for five minutes, followed by 95°C for 
ten minutes, and then allowed to cool overnight. SU-8 2100 photoresist was then added to 
the wafer and subsequently baked at 95°C for three and a half hours, and allowed to cool 
overnight. The wafer was then exposed to 95mJ of energy, baked at 65°C for five 
minutes followed by 95°C for ten minutes and allowed to cool overnight. The wafer was 
then submerged in propylene glycol methyl ether acetate for twenty minutes, and then 
agitated on orbital shaker. Then the wafer was submerged in isopropyl alcohol for five 
minutes and then blow dried with compressed N2. The wafer is then baked at 150°C for 
eight hours and fluoro-silanized overnight (Figure 8).  
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A.     B.    C.  
 
Figure 8. Device Fabrication and Stamps. A. Workflow outlining the device 
fabrication. B. The stamps made from the master devices. C. Devices made from the 
stamps that are used to make the microtissues.  
 
 
 
Stamps made from the master devices were placed in a plasma asher (Plasma 
Asher 1050X) and then in a vacuum with an open vial of silane for at least two hours. 
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Polydimethylsiloxane (PDMS) was made and poured over the stamps and placed in a 
vacuum again for ten minutes. The stamps were then placed upside down in small dishes 
containing PDMS, and then baked for 60°C for an hour. The stamps were then removed 
leaving the imprint of the stamp in the PDMS (Figure 8).  
 
 
Glycation  
 Type I rat tail collagen, 3.5-3.9 mg/mL, (Corning Inc., Corning, NY) was 
incubated in 250mM D-(-)-ribose (Fisher Scientific., Hampton, NH) at 4°C for a 
minimum of five days to a maximum of two months, prior to gelation and seeding. 
Additionally, some aliquots of the collagen and ribose mixture were left open to oxidize 
while incubating, to examine if exposure to oxygen had an effect on collagen’s 
autofluorescence. 
 
 
Pre-glycation versus Post-glycation 
Non-enzymatic glycation of collagen can occur in vitro by one of two methods: 
pre-glycation or post-glycation. Pre-glycation occurs when collagen is incubated in a high 
sugar environment prior to polymerization and gelation. Post-glycation occurs when the 
high sugar environment is introduced after collagen has polymerized and a collagen gel 
has formed. Post-glycation more closely mimics protein glycation in vivo, but the high 
sugar concentration that is necessary for glycation to occur limits the ability to seed cells 
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in the collagen matrix to form microtissues because the osmotic imbalance created by the 
high sugar environment hinders the cell’s ability to grow (Mason & Reinhart-King, 
2013). Whereas with pre-glycation, cells are embedded in within the glycated collagen 
matrix prior to polymerization and gelation therefore are not exposed to the high sugar 
environment, allowing the cells to function as they normally would within the collagen 
matrix.  
 
 
Cell Culture and Subculture  
 NIH/3T3 cells (American Type Culture Collection, Manassas, VA) were thawed 
in a 37°C water bath and then transferred to a T25 flask containing 5 mL of Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% bovine serum (Fisher Scientific, Hampton, 
NH). The cells were then split when confluent. The media was aspirated, the cells were 
washed with 10 mL of phosphate buffered saline (PBS), and the PBS was aspirated. 1 mL 
of Trypsin-EDTA solution was added to the cells and incubated for three minutes. The 
Trypsin-EDTA was then neutralized with 9 mL of DMEM and the cells in the media 
were transferred to a conical tube. The cells were counted using Countess II FL 
Automatic Cell Counter. The cell suspension was then centrifuged for five minutes at 
1400 rpm, and old media was aspirated and replaced with new media. Appropriate 
aliquots of the cell suspension were then added to new culture vessels. Cells were placed 
back in incubator at 37°C with 5% carbon dioxide. Cells were subsequently subcultured 
at 80% confluent or less.  
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Microtissue Seeding and Formation 
 Devices made as described above were sterilized by ultraviolet light for fifteen 
minutes prior to use. For two devices, the collagen solution was prepared with 2300 µL 
of Milli-Q water, 160 µL of 250 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 28 µL of 5% w/v NaHCO3, 400 µL of 10X Media 199, 70 µL of 1M NaOH, 
and 1055 µL of collagen. This solution was prepared and kept on ice to prevent 
polymerization. 1 mL of 0.02% Pluronic F-127 was added to each device and placed in a 
vacuum for ten minutes. The devices were removed from the vacuum, placed on a cold 
block, and the Pluronic F-127 was aspirated. 1 mL of the collagen solution was added to 
the devices and placed in the vacuum again for ten minutes. The devices were then placed 
in a centrifuge for twenty seconds at 3000 rpm.  
Next, NIH/3T3 cells were prepared to be seeded in the collagen matrix in the 
devices. The media was aspirated, the cells were washed with 10 mL of PBS, and then 
the PBS was aspirated. 1 mL of Trypsin-EDTA solution was added to the cells and 
incubated for three minutes. The Trypsin-EDTA solution was then neutralized with 9 mL 
of DMEM and the cells in the media were transferred to a conical tube. The cells were 
counted using Countess II FL Automatic Cell Counter. The cell suspension was then 
centrifuged for five minutes at 1400 rpm, and the media was removed. The cells were 
resuspended in the collagen solution at a concentration of two million cells per mL. 0.5 
mL of cell suspension was added to each device and mixed by gently pipetting. The 
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devices with the cell suspension were placed in a centrifuge for one and a half minutes at 
1200 rpm. This was repeated with a 90° rotation. Excess solution was removed, leaving 
only cells in solution within the wells of the device. The devices were centrifuged again 
for ten seconds at 600 rpm, upside down. This was repeated with a 90° rotation. 0.5 mL 
of PBS was added to the lid, and devices were incubated for thirty minutes upside down 
at 37°C and 5% CO2. PBS was removed and 1.5 mL of DMEM was gently added to the 
devices and incubated overnight.  
 
 
Glycation Confirmation and Analysis of Crosslink Formation 
 Collagen solution was prepared as previously described. However, this solution 
was made twice for each experiment, one with rat tail type I collagen that was incubated 
with 250 mM D-(-)-Ribose, and one with rat tail type I collagen which was not incubated 
with ribose as a control. 750-µL aliquots of the collagen solution were allowed incubated 
at 37°C and 5% CO2 for an hour to polymerize. Each 750-µL collagen gel was digested 
with 1 mL of 0.0025% papain buffer (Roy, Boskey, & Bonassar, 2010). The papain 
buffer solution was made from 50 mM PBS, 2 mM L-cysteine, 2 mM EDTA, and 
0.0025% papain (Sigma-Aldrich, St. Louis, MO). The collagen gel was digested with the 
papain buffer solution for two hours 65°C. Autofluorescence (excitation 360 nm and 
emission 460 nm) and absorbance (340 nm) of the digests was measured using a 
spectrofluorometer (SpectraMax m5, Molecular Devices, San Jose, CA).  
Percent glycation was determined by (Francis-Sedlak et al., 2010):  
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                        %  𝑔𝑙𝑦𝑐𝑎𝑡𝑖𝑜𝑛 = 1−    (!"#$%"!&'(!!"##! )(!"#$#%"!&'(!!"##! ) ∗   100    (1) 
 
where g and c indicate glycated collagen gels and control collagen gels, respectively.  
 
 
Wounding and Analysis 
 Several glycated and non-glycated microtissues were wounded by hand with a 16-
gauge needle in place on a confocal microscope. Recording of the microtissues on the 
confocal microscope started immediately after wounding. Phase contrast images were 
captured every 30 minutes for twenty hours using a Nikon Ti2-E with Andor Dragonfly 
505 System and iXon 888 Life camera equipped with a live cell incubator.  
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RESULTS 
 
 
Confirming Glycation And Analysis  
 
 Collagen gels made with collagen not incubated with ribose as well as collagen 
incubated with 250 mM ribose (glycated collagen) were digested with papain as 
described above and the autofluorescence was measured (Table 1). Additionally two 
types of glycated collagen were used – collagen that was left open to oxidize and 
collagen that was tightly closed. Three digests of each type of collagen were measured. 
Only one digest of the 250 mM ribose incubated with collagen left open showed an 
increase in autofluorescence. An increase in autofluorescence is associated with increased 
AGE accumulation, and so, an increase in autofluorescence would confirm that glycation 
had in fact taken place and AGEs were produced.   
 
Control 
Collagen (au) 
	  
250 mM Ribose + Collagen 
(Closed)  (au)  
250 mM Ribose + Collagen 
(Open) (au)  
296.77 299.18 302.07 
302.32 298.65 416.62 
303.00 304.66 302.32 
  
Table 1. Autofluorescence of collagen gels made with control, 0 mM collagen, 250 
mM ribose incubated with collagen left open to oxidize, and 250 mM ribose with 
collagen. Autofluorescence measured on a SpectraMax m5 - excitation 360 nm, emission 
460 nm.This experiment was repeated again with the same collagen incubated with 250 
mM ribose and the control collagen (collagen not incubated with ribose).  
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Previous research measured collagen autofluorescence using a spectrofluorometer 
at an excitation of 360 nm, but the emission either 460 nm or 465 nm. The digests were 
measured with both these conditions to determine if the difference in emission influenced 
the autofluorescence. The digests measured at exication-360 nm and emission-460 nm 
exhibited a higher autofluorescence than the digests measured at excitation-360 nm and 
emission- 465 nm, but the ratio between the two sample types remained the same (Figure 
9). Regardless of spectrofluorometer settings, there was an increase in autofluorescence 
in the collagen incubated in 250 mM ribose left open to oxidize. However, the increase in 
autofluorescence of the collagen incubated in 250 mM ribose left open to oxidize was not 
as drastic as previously seen (Table 1).  
 
 
Figure 9. Autofluorescence of collagen gel digests with different spectrofluorometer 
emission settings. This graph shows the difference between the same collagen gel digests 
being measured with an emission of 465 nm and 460 nm. Collagen gels were made with 
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collagen incubated with ribose (control), collagen incubated with 250 mM ribose left 
open, and collagen incubated with 250 mM ribose tightly closed.  
 
 
 In an effort to get more consistent results, the autofluorescence of eighteen 
collagen gels were measured, nine collagen gels made from control collagen (collagen 
not incubated with ribose), and nine collagen gels made from collagen incubated with 
250 mM ribose (Figure 10). The visual difference between the gels made with glycated 
collagen (collagen incubated in 250 mM ribose) and the control collagen can be seen in 
Figure 10. However, the autofluorescence of the digests was not consistent (Figure 11), 
and was different from what was previously observed (Figure 8 and Table 1).  
 
Figure 10. Eighteen collagen gel digests before autofluorescence measurement on 
spectrofluorometer. From left to right: columns 1, 2 and 3 are digests of collagen gels 
made from collagen incubated in 250 mM ribose. Columns 4, 5, and 6 are collagen gel 
digests made from collagen not incubated with ribose. Papain buffer was used as the 
blank and is in the bottom left hand corner well.  
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A.  
B.  
 
 
Figure 11. Autofluorescence (au) of eighteen collagen gel digests. A. The 
autofluorescence of nine collagen gel digests made with the same glycated collagen 
(collagen incubated with 250 mM collagen). B. The autofluorescence of nine collagen gel 
digests made with the same control collagen (collagen not incubated with ribose). Papain 
buffer was used as the blank.  	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  The absorbance of the collagen gel digests also has the ability to confirm 
glycation. Since glycation causes browning and AGEs are yellow-brown color (Singh, 
Barden, Mori, & Beilin, 2001), the absorbance of the digest changes with increased AGE 
accumulation (Francis-Sedlak et al., 2010) (Table 2).  
 
Collagen Gel Type Absorbance at 340 nm 
Collagen not incubated with ribose 0.139 
Collagen incubated with 250 mM ribose (open) 0.079 
Collagen incubated with 250 mM ribose (closed) 0.079 
 
Table 2. The absorbance of collagen gel digests measured at 340 nm. The glycated 
collagen had decreased absorbance when compared to control collagen gels. The 
absorbance was the same for both open and closed glycated collagen gels.  
 
 
 
The percent glycation can be determined using the measured absorbance and 
equation (1). The percent glycation was determined to be 43.16% glycated for collagen 
gels made from collagen incubated with 250 mM ribose and left either open or closed.   
 The physical changes in collagen gel digests between those made with collagen 
without ribose and glycated collagen can be visually appreciated (Figure 12 and Figure 
10). The visual changes to the collagen gels contribute to the conclusion that this method 
of incubating collagen with ribose does result in the glycation of collagen.   
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A.   B.  
Figure 12. Visual changes observed in collagen gel digests made from glycated and 
non-glycated collagen. A. Control collagen is the collagen gel digest made from 
collagen not incubated with ribose, open is the glycated collagen gel digest made from 
collagen incubated with 250 mM ribose and left open to oxidize, closed is the glycated 
collagen gel digest made from collagen incubated with 250 mM ribose not open to 
oxidize. B. This picture shows two collagen gel digests of each type of collagen 
previously described. Both pictures show the color change seen in the digests made with 
glycated collagen – the glycated collagen gel digests are much more yellow/brown in 
color, while the control collagen gel digests are pink.  
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Wound Healing in the Microtissues 
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Figure 13. Wound Healing in Two Microtissues Part 1– one made with glycated 
collagen, the other with control (non-glycated) collagen. The microtissue made with 
glycated collagen took much longer to close than the normal microtissue; the wound is 
much larger in the glycated microtissue at 22 hours post wounding, while the normal 
microtissue’s wound is almost fully closed.  
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Figure 14. Wound Healing in Two Microtissues Part 2 – one made with glycated 
collagen, the other with control (non-glycated) collagen. This shows the wound closure of 
two more microtissues. The glycated tissue in this contracted around 15 hours post 
wounding and pulled away from the post holding the tissue in place. It is unclear if the 
wound healed in the microtissue made from glycated collagen. However, prior to 15 
hours, the microtissue made with normal (non-glycated) collagen appeared to be healing 
at a faster rate than the microtissue made with glycated collagen – the gap size was 
smaller in the normal microtissue than in the microtissue made with glycated collagen.  
 
 
 In most cases, the microtissues made with normal (non-glycated) collagen 
appeared to close the wound more quickly than the glycated collagen microtissues 
(Figures 13 and 14). However, some normal microtissues with a larger initial wound size 
did not close at all after being wounded, suggesting that initial wound size influences 
how quickly the wound will close. Likewise, of the four glycated microtissues that were 
made, one of the microtissues had a smaller initial wound and closed at approximately 
ten hours post wounding (Figure 15). More trials would have to be completed to 
determine if glycated collagen affects wound healing time.  
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Figure 15. Glycated Microtissue wound healing. This microtissue had a much smaller 
initial wound when compared to the other microtissues, and this microtissue closed it’s 
wound in approximately ten hours, much faster than the other microtissues, suggesting 
that initial wound size plays an important role in how fast a wound can close. 
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DISCUSSION 	  	  
It is known that diabetic patients have increased amounts of glycated proteins, and 
that glycation changes both the mechanical and biochemical properties of proteins. It is 
not fully understood, however, what direct role glycated collagen plays in the wound 
healing process. The purpose of this analysis was to develop microtissues made with 
glycated collagen, and then wound these glycated collagen microtissues and compare 
time it take for the wound to close in both types of microtissues.  
 
 
 
Glycation Results and Analysis 
 Measuring the autofluorescence of digested collagen gels was not consistent 
enough to successfully confirm glycation. However, the inconsistency seen might have 
been resolved by more thoroughly mixing the collagen solution prior to gelation. In 
figure 10, the nine collagen gel digests made with glycated collagen are not uniform in 
color, despite being made from the same glycated collagen solution. This suggests that 
the collagen solution was not homogeneously mixed, and might have contributed to the 
discrepancies seen when measuring the autofluorescence. AGEs also take several weeks 
to months to form, and not all AGEs exhibit autofluorescence. It is possible that of the 
AGEs that did form in the collagen incubated with ribose, only a small percentage were 
those AGEs that demonstrate autofluorescence, which may also help explain the lack of 
autofluorescence seen in some of the glycated collagen samples.  
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 Measuring the absorbance of the collagen gel digests is often used in conjunction 
with measuring the autofluorescence to confirm glycation (Francis-Sedlak et al., 2010). 
Measuring the absorbance of the collagen gel digests proved to be more successful. Using 
the absorbance, it was determined that the percent glycation of the collagen incubated 
with ribose was 43.16%. There was also a visual change seen in the digests made from 
glycated collagen. The collagen gel digests made from normal collagen were pink in 
color. However, the collagen gel digests made from collagen that was incubated in ribose 
were much paler and yellow in color than the control digests. Glycation and the 
formation of AGEs produce a yellow/brown color. Taking this along with using the 
absorbance of the collagen gel digests to calculate the percent glycated; it can confirm 
that this method of incubating ribose with collagen produces glycated collagen that can 
be successfully incorporated into microtissues.  
 
 
Microtissue Wounding and Healing 
 
Of the four microtissues made with glycated collagen that were wounded, one had 
a very small initial wound and closed faster than expected (Figure 15), one contracted 
and broke away from one pillar holding the microtissue in place (Figure 14), one seemed 
to have worked as expected (Figure 13), and the recording of the final microtissue was 
blurry and we were unable to confirm if the wound had closed. These experiments should 
be repeated with more microtissues made from glycated collagen to determine an average 
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time required to close wound in microtissues made from glycated collagen and then that 
can be compared to the average time required for normal microtissues to heal after being 
wounded. 
Additionally, based on the results it is suggested that initial wound size plays a 
large role in how quickly a wound will close. This creates a potential problem because in 
order to have the most accurate results the initial wound would have to be the exact same 
size in both the normal microtissue and the microtissue made with glycated collagen. Our 
current method does not allow for all wounds to be the exact same size (Figures 13-15).  
 
 
Ideas for Future Research and Implications 
 
 Diabetes is a growing epidemic with the number of those affected growing daily. 
Designing a method to produce microtissues made from glycated collagen is important 
because it allows the effects of glycation on the wound healing process to be isolated, and 
therefore, studied directly. The glycated collagen microtissue model can be used in 
various other assays, such as an assay to study signaling dynamics. Studying various 
signaling molecules, such as calcium and cyclic adenosine monophosphate, in glycated 
collagen microtissues may reveal the role that glycation plays in the wound healing 
process.  Studying the wound healing process in diabetics can lead to the ability to 
manipulate the process, improve the effectiveness of treatment, reduce costs of treatment, 
and therefore improve the quality of life for those individuals living with diabetes.  
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